Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update Licensed Jenrin Discovery’s extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic...

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study Management to host conference call and webcast this morning at 8:30 a.m. EDTJenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with...